• Mult. Scler. · Apr 2018

    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.

    • Marloes Hj Hagens, Joep Killestein, Maqsood M Yaqub, Guus Ams van Dongen, Adriaan A Lammertsma, Frederik Barkhof, and Bart Nm van Berckel.
    • Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands/MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
    • Mult. Scler. 2018 Apr 1; 24 (4): 543-545.

    AbstractPrevious studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…